




<https://www.a4i.me/>



What is A4i?

A4i (The App4Independence) is a digital therapeutic (DTx) and digital biomarker platform for severe mental illnesses (SMIs).

The platform features a mobile application used by patients and a clinical portal to support care coordination by providers. A4i is a trans-diagnostic platform which has cross cutting applications across many SMIs. The platform has active deployments to manage schizophrenia. A4i addresses critical gaps during pivotal points in the recovery process by providing (patent pending) tools that address auditory hallucinations, data collection for clinical decision support and data-driven readmission/relapse risk-detection. Additional solutions are being developed to address indications for addictions (e.g. opioid use disorder), severe mood (e.g., bipolar disorder), and developmental disability populations.

A4i is a Joint Venture between Canada's largest mental health teaching hospital, The Centre for Addiction & Mental Health (CAMH) and MEMOTEXT, a leading provider for digital patient engagement and DTx solutions.

Severe Mental Illness

Complex patient journeys, very limited in-person outpatient care resources, challenged provider and treatment plan engagement with high non-adherence rates, high rates of risk and distress alongside extensive and costly crisis service utilization.

- 23% are readmitted within 30 days of discharge.
- \$470 Billion in direct costs to healthcare
- \$500+ Billion Total Addressable Market.

Value of A4i

A4i is co-designed with patients and clinicians using a transdiagnostic approach to multi-symptom remediation

- Enhanced clinical decision support through highly adaptive patient-provider engagement and communications
- Readmission-risk prediction through proactive analytics and predictive machine learning
- Significant early improvements in several symptom domains
- Early digital biomarkers (feature predictors) identified related to risk of relapse/readmission.
- **Patent(s) Pending: Audio hallucination detection feature**
- Peer Reviewed with multiple concurrent clinical efficacy trials, adoption and usability validation underway
- Regulatory (FDA) pathway towards Software as a Medical Device (SaMD)

Traction

- 2019 Early Research & Codesign
- 2020 Feasibility Study Published
- 2021 CIHR Funded Randomized Control Study
- 2022 Opioid addiction indication development and trial funded.
- 2022 CalMHSA Pilot with Riverside University Health System expansion
- ~\$1M in funding to date including SAFE from CAMH
- Early Pilot Revenues and business model validations

About Us

- Led by cross-functional experienced clinical, digital health, digital therapeutics, clinical and commercialization team.
- Winner of JLABs Quickfire Challenge (Toronto)
- Creative Destruction Labs (CDL) Accelerator Health Diagnostics Graduate
- Scientific American's 1 of 10 startups changing healthcare

Contact: Amos Adler, CEO | amos@memotext.com | <https://a4i.me>

